
News|Articles|August 24, 2026
- A Recap of CPHI Milan 2026 eBook
- Volume 50
From Detection to Prediction: Modern Analytical Approaches for Nitrosamine Risk
Author(s)Chris Williams
Fact checked by: Ronald Panarotti
Nitrosamine control is about understanding why nitrosamines form, where they may form, and how to prevent their formation.
Advertisement
Advertisement
Nitrosamines have been known carcinogens for decades, but their emergence in pharmaceutical products in 2018 transformed them into a central regulatory and analytical priority.1 What began as a targeted investigation into a handful of small nitrosamines has since expanded into a complex, mechanism-driven discipline requiring predictive assessment, structural evaluation, and highly sensitive analytical methods.
Related to this article

The FDA’s new CBER Safety Council separates post-market biologics safety review from approvals, raising oversight for cell and gene therapy developers.

EU GMP Annex 22: AI Pulse Check panelists say most manufacturers aren’t ready, static AI models likely stay central, and local AI deployment grows.

How confident is the bio/pharma workforce heading into 2027? PharmTech wants to find out, and we need your input.

Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.

PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.

Nate Edwards of Arya Consulting, Elisabeth Gardiner of Tevard Biosciences, and Donny Xu of the RTW Institute discuss global competition for rare disease therapies.
Advertisement
Advertisement


